Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer'sdisease to rats
Autore:
Dahlin, M; Bjork, E;
Indirizzi:
Uppsala Univ, Dept Pharm, Div Pharmaceut, Ctr Biomed, SE-75123 Uppsala, Sweden Uppsala Univ Uppsala Sweden SE-75123 tr Biomed, SE-75123 Uppsala, Sweden
Titolo Testata:
INTERNATIONAL JOURNAL OF PHARMACEUTICS
fascicolo: 2, volume: 212, anno: 2001,
pagine: 267 - 274
SICI:
0378-5173(20010116)212:2<267:NAOAPA>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
INTRANASAL ABSORPTION; CEREBROSPINAL-FLUID; OLFACTORY BULBS; DELIVERY; DRUG; PHARMACOKINETICS; BRAIN; BIOAVAILABILITY; APOMORPHINE; TRANSPORT;
Keywords:
nasal administration; acetylcholinesterase (AChE) inhibitor; brain deliver; olfactory pathway; rat; cerebrospinal fluid (CSF);
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Bjork, E Uppsala Univ, Dept Pharm, Div Pharmaceut, Ctr Biomed, POB 580, SE-75123 Uppsala, Sweden Uppsala Univ POB 580 Uppsala Sweden SE-75123 123 Uppsala, Sweden
Citazione:
M. Dahlin e E. Bjork, "Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer'sdisease to rats", INT J PHARM, 212(2), 2001, pp. 267-274

Abstract

The nasal route has been receiving attention for the administration of systemically active drugs because delivery is convenient, reliable and rapid. The aims of this study were to investigate the systemic absorption of nasally administered (3aS)-cis-1, 2, 3, 3a, 8, 8a-hexahydro-1, 3a, 8-trimethyl-pyrrolo-[2,3b]-indol-5-yl 3, 4 dihydro-2-isoquinolincarboxylate (NXX-066), aphysostigmine analogue, in rats and to compare the uptake of the drug intothe cerebrospinal fluid (CSF) after nasal and intravenous administration. NXX-066 (3 mu mol/kg) was administered to both nostrils or into the vena jugularis of male Sprague-Dawley rats. Blood and CSF samples were obtained atregular intervals from the arteria carotis and by cisternal puncture, respectively. The concentrations of NXX-066 in the blood and CSF samples were measured using HPLC with fluorescence detection. NXX-066 was absorbed rapidly after nasal administration with the peak concentration occurring within 1.5 min. The nasal bioavailability of NXX-066 was 100+/-30% and the elimination from plasma was as rapid as that following intravenous administration. Low concentrations of NXX-066 were detected in the CSF after both intravenous and nasal administration. In conclusion, NXX-066 was rapidly and totallyabsorbed into the systemic circulation and uptake into the CSF was not enhanced by nasal administration in rats. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 07:27:43